Piflufolastat F 18: diagnostic first approval
SJ Keam - Molecular Diagnosis & Therapy, 2021 - Springer
Abstract Piflufolastat F 18 (PYLARIFY®) is an 18 F-labelled diagnostic imaging agent that
has been developed by Progenics Pharmaceuticals Inc., a Lantheus company, for positron …
has been developed by Progenics Pharmaceuticals Inc., a Lantheus company, for positron …
Molecular imaging of bone metastases and their response to therapy
Bone metastases are common, especially in more prevalent malignancies such as breast
and prostate cancer. They cause significant morbidity and draw on health-care resources …
and prostate cancer. They cause significant morbidity and draw on health-care resources …
[HTML][HTML] Prostate-specific membrane antigen reporting and data system version 2.0
RA Werner, PE Hartrampf, WP Fendler, SE Serfling… - European urology, 2023 - Elsevier
Abstract Prostate-specific Membrane Antigen Reporting and Data System (PSMA-RADS)
was introduced for standardized reporting, and PSMA-RADS version 1.0 allows …
was introduced for standardized reporting, and PSMA-RADS version 1.0 allows …
Piflufolastat F-18 (18F-DCFPyL) for PSMA PET imaging in prostate cancer
Introduction Accurate imaging is essential for staging prostate cancer and guiding
management decisions. Conventional imaging modalities are hampered by a limited …
management decisions. Conventional imaging modalities are hampered by a limited …
18F-DCFPyL PET/CT for Initially Diagnosed and Biochemically Recurrent Prostate Cancer: Prospective Trial with Pathologic Confirmation
GA Ulaner, B Thomsen, J Bassett, R Torrey, C Cox… - Radiology, 2022 - pubs.rsna.org
Background Prostate-specific membrane antigen (PSMA) PET is standard for newly
diagnosed high-risk and biochemically recurrent (BCR) prostate cancer. Although studies …
diagnosed high-risk and biochemically recurrent (BCR) prostate cancer. Although studies …
[HTML][HTML] [18F] DCFPyL PET/CT for imaging of prostate cancer
Prostate-specific membrane antigen (PSMA)-directed positron emission tomography (PET)
has gained increasing interest for imaging of men affected by prostate cancer (PC). In recent …
has gained increasing interest for imaging of men affected by prostate cancer (PC). In recent …
[HTML][HTML] Clinical applications of PSMA PET examination in patients with prostate cancer
Simple Summary The prostate specific membrane antigens, abbreviated as PSMAs, are type
II membrane proteins that are highly ex-pressed on the surface of malignant prostate tissue …
II membrane proteins that are highly ex-pressed on the surface of malignant prostate tissue …
Impact of 18F-DCFPyL PET on Staging and Treatment of Unfavorable Intermediate or High-Risk Prostate Cancer
A Basso Dias, A Finelli, G Bauman, P Veit-Haibach… - Radiology, 2022 - pubs.rsna.org
Background Data regarding 2-(3-{1-carboxy-5-[(6-[18F] fluoro-pyridine 3-carbonyl)-amino]-
pentyl}-ureido)-pentanedioic acid (18F-DCFPyL) PET in primary staging of prostate cancer …
pentyl}-ureido)-pentanedioic acid (18F-DCFPyL) PET in primary staging of prostate cancer …
[HTML][HTML] Enzymatic synthesis of fluorinated compounds
X Cheng, L Ma - Applied Microbiology and Biotechnology, 2021 - Springer
Fluorinated compounds are widely used in the fields of molecular imaging, pharmaceuticals,
and materials. Fluorinated natural products in nature are rare, and the introduction of …
and materials. Fluorinated natural products in nature are rare, and the introduction of …
A comparison of 18F-DCFPyL, 18F-NaF, and 18F-FDG PET/CT in a prospective cohort of men with metastatic prostate cancer
A Fourquet, A Rosenberg, E Mena… - Journal of Nuclear …, 2022 - Soc Nuclear Med
18F-DCFPyL, 18F-sodium fluoride (18F-NaF), and 18F-FDG PET/CT were compared in a
prospective cohort of men with metastatic prostate cancer (PCa). Methods: Sixty-seven men …
prospective cohort of men with metastatic prostate cancer (PCa). Methods: Sixty-seven men …